DDX39B and melanoma: Compared with primary lesions, DDX39B was augmented in metastatic prostate cancer tissues, but not in melanoma and breast cancer, suggesting that DDX39B may serve as a potential predictor of metastasis risk for certain cancers, including CRC and prostate cancer (Supplementary Fig. 2).